Skip to main content
. 2018 Nov 5;9:2552. doi: 10.3389/fimmu.2018.02552

Figure 4.

Figure 4

CD45RA– CD27+ Central Memory/Transitional Memory (TCM/TM) CD4+ T cell subset is significantly depleted by CD16.NK-92 and alefacept in healthy donors. (A) Representative flow cytometry plots of CD16.NK-92 killing of CD4+ T cell subsets in healthy donor at E:T = 0.5:1, 19 h co-culture with 10 μg/mL alefacept or IgG1 control antibody. (B) CD2 MFI of CD4+ T cell subsets. (C) Percent cytotoxicity of CD4+ T cell subsets (same CD4+ T cell donors from Figure 3) co-cultured with CD16.NK-92 for 19 h at E:T = 0.5:1 with 10 μg/mL alefacept or IgG1 control antibody, as measured by absolute count flow cytometry. (D) Percent of whole representations of CD4+ T cell subsets by donor with and without treatment. (E) Absolute count of CD27+ CD45RA+ TCM/TM subset with no treatment and with CD16.NK-92 at E:T = 0.5:1 and 10 μg/mL alefacept or IgG1 control antibody after 19 h in co-culture. Mean and SEM are shown for 6 healthy donors, **P ≤ 0.01, ***P ≤ 0.001. For percent cytotoxicity graph, statistical significance between IgG1 and alefacept conditions are indicated with black bars and statistical significance between cell subsets with alefacept are indicated with red bars.